Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Eisai
Woman Max 99 years
Eisai Inc
Update Il y a 4 ans
An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7080 in Combination with Carboplatin + Gemcitabine versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients with Platinum-Sensitive Recurrent Ovarian Cancer by CA125
• Phase Ib: to define the maximum tolerated dose (MTD)/ recommended Phase II of E7080 administered in combination with carboplatin + gemcitabine in patients with platinum-sensitive recurrent ovarian ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman Max 99 years
Eisai Limited
Update Il y a 4 ans
An open-label, randomized phase II study of the efficacy and safety of indisulam (E7070) in combination with capecitabine versus capecitabine monotherapy for the treatment of metastatic breast cancer patients following prior anthracycline and taxane therapy
To compare the efficacy, safety and tolerability of indisulam (I) in combination with capecitabine (C) versus capecitabine (C) monotherapy in patients with metastatic breast cancer following prior ant...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Eisai Limited
Update Il y a 4 ans
Open label Extension Study Following Double-blind, Randomized, Placebo-controlled, Multicentre Study to Assess Efficacy and Safety of Adjunctive Zonisamide in Myoclonic Seizures associated with Idiopathic Generalized Epilepsy
To assess the long-term safety of zonisamide in subjects with myoclonic seizures.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Eisai Limited
Update Il y a 4 ans
A 2-year, Randomized, Double-blind, Placebo-controlled, Multi-center, Phase II-III Study to Evaluate the Efficacy and Safety of Oral Ranirestat (40 and 80 mg) in Mild to Moderate Diabetic Sensorimotor Polyneuropathy
To determine the effect of 40 mg and 80 mg ranirestat on peroneal motor nerve conduction velocity relative to placebo in subjects with mild to moderate diabetic sensorimotor polyneuropathy
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Eisai Limited
Update Il y a 4 ans
A 52-week, multicentre, open label extension study of the safety, tolerability and efficacy of donepezil (Aricept) in Parkinson's disease patients with dementia
To assess the safety and tolerability (including an assessment of motor symptoms using the UPDRS) of open label 5-10 mg/day Aricept® in Parkinson's disease patients with dementia, who have completed t...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Eisai
Update Il y a 4 ans
Étude E7080-G000-211 : étude de phase 2 randomisée comparant l’efficacité du lenvatinib oral à 18 mg par jour à 24 mg par jour chez des patients ayant un cancer de la thyroïde différencié réfractaire à l’iode radioactif 131.
Le cancer de la thyroïde différencié représente environ 90% de tous les cancers de la thyroïde, mais il existe peu de traitements efficaces pour le cancer de la thyroïde réfractaire à l’iode radioacti...
Country
France
organs
Thyroïde
Specialty
Thérapies Ciblées
Essai ouvert aux inclusions
More information
Woman and Man Max 99 years
Eisai Limited
Update Il y a 4 ans
Estudio aleatorizado, doble ciego, controlado con placebo y de grupos paralelos con una fase de extensión abierta para evaluar el efecto de perampanel (E2007) en la cognición, el crecimiento, la seguridad, la tolerabilidad y la farmacocinética cuando se administra como terapia adyuvante en adolescentes (de 12 a menos de 18 años de edad) con crisis de inicio parcial insuficientemente controladas. A Randomized, Double-blind, Placebo-controlled, Parallel-group Study With an Open-label Extension Phase to Evaluate the Effect of Perampanel (E2007) on Cognition, Growth, Safety, Tolerability, and Pharmacokinetics When Administered as an Adjunctive Therapy in Adolescents (12 to less than 18 years of age) With Inadequately Controlled Partial-onset Seizures
Comparar el efecto a corto plazo de perampanel y placebo en la cognición empleando el sistema Cognitive Drug Research (CDR) cuando se administra como tratamiento adjuvante a adolescentes (12 a menos ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Eisai Medical Research Inc
Update Il y a 4 ans
Bioavailability of a New Oral Suspension of E3810
The primary objective of this study was to evaluate the bioavailability of a new rabeprazole formulation, consisting of enteric-coated microgranules, relative to the currently marketed 10-mg tablet fo...
Country
None
organs
None
Specialty
None
More information
Previous
4
5
6
7
8
9